NCT01421043View on ClinicalTrials.gov

A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Healthy
Interventions
DRUG

triazolam liquid oral drops

0.25 mg single dose oral drops

DRUG

triazolam tablets

0.25 mg single oral dose

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01421043 - A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects | Biotech Hunter | Biotech Hunter